Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D09GGJ
|
||||
| Former ID |
DCL000285
|
||||
| Drug Name |
CVT-124
|
||||
| Synonyms |
Adentri; Naxifylline; ENX cpd; BG 9719; BG9719; CVT 124; BG-9719; 1,3-ENX; 1,3-dipropyl-8-(2-(5,6-epoxy)norbornyl)xanthine; 8-((2S,5,6-Exo)-5,6-epoxy-2-norbonyl)-1,3-dipropylxanthine
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Autoimmune diabetes [ICD10:E08-E13] | Discontinued in Phase 3 | [1] | ||
| Company |
CV Therapeutics
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C18H24N4O3
|
||||
| Canonical SMILES |
CCCN1C2=C(C(=O)N(C1=O)CCC)NC(=N2)C3CC4CC3C5C4O5
|
||||
| InChI |
1S/C18H24N4O3/c1-3-5-21-16-12(17(23)22(6-4-2)18(21)24)19-15(20-16)11-8-9-7-10(11)14-13(9)25-14/h9-11,13-14H,3-8H2,1-2H3,(H,19,20)/t9-,10+,11+,13+,14-/m1/s1
|
||||
| InChIKey |
OQCJPFYWFGUHIN-VSEIDBEKSA-N
|
||||
| CAS Number |
CAS 166374-49-8
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Adenosine A1 receptor | Target Info | Antagonist | [2], [3] | |
| KEGG Pathway | cGMP-PKG signaling pathway | ||||
| cAMP signaling pathway | |||||
| Sphingolipid signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Morphine addiction | |||||
| NetPath Pathway | TCR Signaling Pathway | ||||
| RANKL Signaling Pathway | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Reactome | Adenosine P1 receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | Nucleotide GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015498) | ||||
| REF 2 | Adenosine receptors and cardiovascular disease: the adenosine-1 receptor (A1) and A1 selective ligands. Cardiovasc Toxicol. 2003;3(1):71-88. | ||||
| REF 3 | CV Therapeutics. Company report from CV Therapeutics, Inc. CV Therapeutics. 2009. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.